scholarly journals Are Plasma Levels of Atrial Natriuretic Peptide, N-Terminal ProANP, and Brain Natriuretic Peptide Affected by the Presence of Coronary Artery Disease?

Circulation ◽  
2004 ◽  
Vol 109 (25) ◽  
Author(s):  
Toshio Nishikimi ◽  
Hiroaki Matsuoka
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Atrial Natriuretic Peptide ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Artery Disease ◽  
Atrial Natriuretic

scholarly journals N-terminal Pro-brain Natriuretic Peptide plasma levels are Associated With a Short-Term Diagnosis of Cancer in Patients with Coronary Artery Disease

2020 ◽  
Author(s):  
José Tuñón ◽  
Álvaro Aceña ◽  
Ana Pello ◽  
Sergio Ramos-Cillán ◽  
Juan Martínez-Milla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
High Sensitivity ◽  
Short Term ◽  
Artery Disease

Abstract Background N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the short term. Methods We studied 962 patients with stable coronary artery disease and free of cancer and heart failure at baseline. NT-proBNP, galectin-3, monocyte chemoattractant protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I (hsTnI), and calcidiol (vitamin D) plasma levels were assessed. The primary outcome was new CD. Results After 5.40 (2.81-6.94) years of follow-up, 59 patients received a CD. NT-proBNP [HR 1.036 CI (1.015-1.056) per increase in 100 pg/ml; p=0.001], previous atrial fibrillation [HR 3.140 CI (1.196-8.243); p=0.020], and absence of previous heart failure [HR 0.067 CI (0.006-0.802); p=0.033] were independent predictors of a receiving a CD in first three years of follow-up. None of the variables analyzed predicted a CD beyond this time. A previous history of heart failure was present in 3.3% of patients receiving a CD in the first three years of follow-up, in 0.0% of those receiving this diagnosis beyond three years, and in 12.3% of patients not developing cancer (p=0.036). Conclusions In patients with coronary artery disease, NT-proBNP is an independent predictor of CD in the first three years of follow-up but not later, suggesting that it could be detecting subclinical undiagnosed cancers. The existence of previous heart failure does not account for these differences. New studies in large populations are needed to confirm these findings.

Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease

2012 ◽  
Vol 123 (10) ◽  
pp. 601-610 ◽  
Author(s):  
Stephan von Haehling ◽  
Jana Papassotiriou ◽  
Oliver Hartmann ◽  
Wolfram Doehner ◽  
Konstantinos Stellos ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Prognostic Value ◽  
Care Hospital ◽  
Catheterization Laboratory ◽  
Coronary Syndrome ◽  
Artery Disease ◽  
Atrial Natriuretic

In the present study, we investigated the prognostic value of MR-proANP (mid-regional pro-atrial natriuretic peptide). We consecutively evaluated a catheterization laboratory cohort of 2700 patients with symptomatic CAD (coronary artery disease) [74.1% male; ACS (acute coronary syndrome), n=1316; SAP (stable angina pectoris), n=1384] presenting to the Cardiology Department of a large primary care hospital, all of whom underwent coronary angiography. Serum MR-proANP and other laboratory markers were sampled at the time of presentation or in the catheterization laboratory. Clinical outcome was assessed by hospital chart analysis and telephone interviews. The primary end point was all-cause death at 3 months after enrolment. Follow-up data were complete in 2621 patients (97.1%). Using ROC (receiver operating characteristic) curves, the AUC (area under the curve) of 0.73 [95% CI (confidence interval), 0.67–0.79] for MR-proANP was significantly higher compared with 0.58 (95% CI, 0.55–0.62) for Tn-I (troponin-I; DeLong test, P=0.0024). According to ROC analysis, the optimal cut-off value of MR-proANP was at 236 pmol/l for all-cause death, which helped to find a significantly increased rate of all-cause death (n=76) at 3 months in patients with elevated baseline concentrations (≥236 pmol/l) compared with patients with a lower concentration level in Kaplan–Meier survival analysis (log rank, P<0.001). The predictive performance of MR-proANP was independent of other clinical variables or cardiovascular risk factors, and superior to that of Tn-I or other cardiac biomarkers (all: P<0.0001). MR-proANP may help in the prediction of all-cause death in patients with symptomatic CAD. Further studies should verify its prognostic value and confirm the appropriate cut-off value.

scholarly journals Association of 2238T>C Polymorphism of the Atrial Natriuretic Peptide Gene With Coronary Artery Disease in Afro-Caribbeans With Type 2 Diabetes

2012 ◽  
Vol 25 (5) ◽  
pp. 524-527 ◽  
Author(s):  
Laurent Larifla ◽  
Suriya Maimaitiming ◽  
Fritz-Line Velayoudom-Cephise ◽  
Severine Ferdinand ◽  
Anne Blanchet-Deverly ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Artery Disease ◽  
Peptide Gene ◽  
Atrial Natriuretic

Estimation of the secretion rate of atrial natriuretic peptide from the coronary sinus in coronary artery disease

1988 ◽  
Vol 62 (1) ◽  
pp. 56-58 ◽  
Author(s):  
Yasunobu Hirata ◽  
Takashi Serizawa ◽  
Osami Kohmoto ◽  
Tokuichiro Sugimoto ◽  
Hiroaki Matsuoka ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Coronary Sinus ◽  
Secretion Rate ◽  
Artery Disease ◽  
Atrial Natriuretic
Sign in / Sign up

Export Citation Format

Share Document